🚀 VC round data is live in beta, check it out!
SELLAS Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for SELLAS Life Sciences and similar public comparables like Allergy Therapuetics, MedinCell, Jade Biosciences, Chabiotech and more.
SELLAS Life Sciences Overview
About SELLAS Life Sciences
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Founded
2006
HQ
Employees
15
Website
Sectors
Financials (FY)
EV
$836M
SELLAS Life Sciences Financials
SELLAS Life Sciences reported last fiscal year revenue of — and negative EBITDA of ($28M).
In the same fiscal year, SELLAS Life Sciences generated ($28M) in EBITDA losses and had net loss of ($27M).
Revenue (LTM)
SELLAS Life Sciences P&L
In the most recent fiscal year, SELLAS Life Sciences reported revenue of — and EBITDA of ($28M).
SELLAS Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($28M) | XXX | XXX | XXX |
| Net Profit | ($30M) | XXX | ($27M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SELLAS Life Sciences Stock Performance
SELLAS Life Sciences has current market cap of $907M, and enterprise value of $836M.
Market Cap Evolution
SELLAS Life Sciences' stock price is $5.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $836M | $907M | 3.9% | XXX | XXX | XXX | $-0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSELLAS Life Sciences Valuation Multiples
SELLAS Life Sciences trades at (29.6x) EV/EBITDA.
EV / Revenue (LTM)
SELLAS Life Sciences Financial Valuation Multiples
As of April 11, 2026, SELLAS Life Sciences has market cap of $907M and EV of $836M.
Equity research analysts estimate SELLAS Life Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SELLAS Life Sciences has a P/E ratio of (29.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $907M | XXX | $907M | XXX | XXX | XXX |
| EV (current) | $836M | XXX | $836M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (29.6x) | XXX | XXX | XXX |
| EV/EBIT | (26.3x) | XXX | (29.6x) | XXX | XXX | XXX |
| P/E | (29.8x) | XXX | (33.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (29.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SELLAS Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SELLAS Life Sciences Margins & Growth Rates
SELLAS Life Sciences' revenue in the last fiscal year grew by —.
SELLAS Life Sciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.9M for the same period.
SELLAS Life Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (10%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SELLAS Life Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Allergy Therapuetics | XXX | XXX | XXX | XXX | XXX | XXX |
| MedinCell | XXX | XXX | XXX | XXX | XXX | XXX |
| Jade Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Chabiotech | XXX | XXX | XXX | XXX | XXX | XXX |
| CytomX Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SELLAS Life Sciences M&A Activity
SELLAS Life Sciences acquired XXX companies to date.
Last acquisition by SELLAS Life Sciences was on XXXXXXXX, XXXXX. SELLAS Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SELLAS Life Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSELLAS Life Sciences Investment Activity
SELLAS Life Sciences invested in XXX companies to date.
SELLAS Life Sciences made its latest investment on XXXXXXXX, XXXXX. SELLAS Life Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SELLAS Life Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SELLAS Life Sciences
| When was SELLAS Life Sciences founded? | SELLAS Life Sciences was founded in 2006. |
| Where is SELLAS Life Sciences headquartered? | SELLAS Life Sciences is headquartered in United States. |
| How many employees does SELLAS Life Sciences have? | As of today, SELLAS Life Sciences has over 15 employees. |
| Who is the CEO of SELLAS Life Sciences? | SELLAS Life Sciences' CEO is Angelos M. Stergiou. |
| Is SELLAS Life Sciences publicly listed? | Yes, SELLAS Life Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of SELLAS Life Sciences? | SELLAS Life Sciences trades under SLS ticker. |
| When did SELLAS Life Sciences go public? | SELLAS Life Sciences went public in 2008. |
| Who are competitors of SELLAS Life Sciences? | SELLAS Life Sciences main competitors are Allergy Therapuetics, MedinCell, Jade Biosciences, Chabiotech. |
| What is the current market cap of SELLAS Life Sciences? | SELLAS Life Sciences' current market cap is $907M. |
| Is SELLAS Life Sciences profitable? | No, SELLAS Life Sciences is not profitable. |
| What is the current net income of SELLAS Life Sciences? | SELLAS Life Sciences' last 12 months net income is ($30M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.